Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 3/20 | 0.60 |
| ▸ | FASN | P49327 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 2/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459209 | 0.91 | ACHE (0.65) | HPGDMEN1KMT2AMGLLHSD11B1 | |
| SCHEMBL24628704 | 0.88 | MGLL (0.52) | SMN1; SMN2HPGDMAPK1LMNAMEN1 | |
| SCHEMBL8166304 | 0.87 | HSD11B1 (0.61) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7238728 | 0.85 | HTT (0.70) | SMN1; SMN2HPGDMAPK1HTR2BHTR1A | |
| SCHEMBL13952158 | 0.85 | HSD11B1 (0.54) | SMN1; SMN2HPGDLMNAMEN1KMT2A | |
| SCHEMBL8168302 | 0.85 | PDE4B (0.57) | SMN1; SMN2LMNAALDH1A1HTR2BHSD11B1 | |
| SCHEMBL3637213 | 0.84 | GRM5 (0.72) | MAPK1LMNA | |
| SCHEMBL8159195 | 0.83 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDMAPK1LMNAMEN1 | |
| SCHEMBL8161198 | 0.82 | HSD11B1 (0.51) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL13597142 | 0.82 | HDAC3 (0.58) | SMN1; SMN2HPGDMAPK1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | SMN1; SMN2 2385/4885HPGD 3544/4885MAPK1 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.